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Abstract 
Cardiovascular risk factors, especially hypertension, are also major risk factors for Alzheimer’s 
disease (AD). To elucidate the underlying vascular origin of neurodegenerative processes in AD, 
we investigated the relation between systolic blood pressure (SBP) cerebral blood flow (CBF) and 
vasoreactivity with brain structure and function in a 16-18 months old double transgenic 
AβPPswe/PS1dE9 (AβPP/PS1) mouse model for AD. These aging AβPP/PS1 mice showed an 
increased SBP linked to a declined regional CBF. Furthermore, using advanced MRI techniques, 
decline of functional and structural connectivity was revealed in the AD-like mice coupled to 
impaired cognition, increased locomotor activity, and anxiety-related behavior. Post mortem 
analyses demonstrated also increased neuroinflammation, and both decreased synaptogenesis and 
neurogenesis in the AβPP/PS1 mice. Additionally, deviant levels of fatty acids and sterols were 
present in the brain tissue of the AβPP/PS1 mice indicating maladapted brain fatty acid metabolism. 
Our findings suggest a link between increased SBP, decreased cerebral hemodynamics and 
connectivity in an AD mouse model during aging, leading to behavioral and cognitive impairments. 
As these results mirror the complex clinical symptomatology in the prodromal phase of AD, we 
suggest that this AD-like murine model could be used to investigate prevention and treatment 
strategies for early AD patients. Moreover, this study helps to develop more efficient therapies and 
diagnostics for this very early stage of AD. 
Key words: Blood pressure; Cerebral blood flow; Alzheimer's disease; Functional connectivity; 
Neuropathology; Neurodegeneration: experimental models. 
Introduction 
Dementia has become a public health problem in 
the aging world population [1, 2]. Alzheimer’s disease 
(AD) is responsible for most dementia cases followed 
by vascular dementia (VaD) [3, 4]. AD is characterized 
by brain atrophy and a gradual cognitive decline 
caused by neuronal death and loss of synapses in 
brain regions involved in learning and memory 
processes (e.g. temporal and frontal lobes) [5, 6]. 
Already the early stages of AD are characterized 
by the accumulation of Aβ affecting specific brain 
regions like the forebrain and medial temporal lobe 
structures like hippocampus, amygdala and 
entorhinal cortex [7-9]. Almost all insoluble Aβ is 
accumulated within the neuritic plaques and cerebral 
vessel walls [5].  
Epidemiological and clinical studies revealed 
that AD and VaD share common vascular related risk 
factors such as hypertension, diabetes, 
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hyperlipidemia, cerebrovascular disease, and 
arrhythmia [10-16]. Furthermore, it has been shown 
that vascular risk factors can influence the 
development of AD pathology (the vascular 
hypothesis) [17]. A recent study showed that 
hypertension affects the expression of tau as well as 
that of Aβ in an AD mouse model [18]. Further 
evidence supporting this link between hypertension 
and AD comes from clinical studies indicating that 
antihypertensives may reduce the development of AD 
[19, 20]. Other clinical studies suggested that resting 
cerebral blood flow (CBF) is decreased among 
hypertensive patients as opposed to that of 
normotensive subjects [21-25]. In elderly patients a 
decreased CBF has been shown to increase 
hippocampal and amygdalar atrophy [26, 27]. 
Therefore, an impaired or diminished cerebral 
perfusion may play a role in the development of AD 
via decreased delivery of oxygen in ischemia-sensitive 
brain regions like the hippocampus, inducing 
neurodegeneration and subsequent cognitive decline 
[28]. Notably, maladapted cerebral hemodynamics 
could lead to alteration in structural and functional 
connectivity in the brain represented by white matter 
lesions/hyperintensities. Impaired functional 
connectivity is also found in AD patients [29-31] and 
additionally, a link between the incidence of white 
matter lesions and the severity of the underlying AD 
pathology has been reported [32-34]. Many studies 
have shown the relationship between increased blood 
pressure in mid-life and cognitive decline or AD in 
late-life [35, 36] indicating the relevance of proper 
blood pressure maintenance. 
Therefore, to elucidate the underlying vascular 
origin of neurodegenerative processes in AD, we 
investigate the relation between vascular parameters 
(systolic blood pressure (SBP), cerebrovascular 
density, cerebral perfusion and vasoreactivity), 
functional and structural connectivity, and 
postmortem markers for neuroinflammation, 
neurogenesis, postsynaptic density, and levels of fatty 
acids and sterols and, in relation to cognition in the 
AβPPswe/PS1dE9 (AβPP/PS1) mouse model for AD. 
To develop and evaluate potential therapeutic 
targets for early stages in AD it is necessary to 
understand underlying (neurovascular) pathological 
processes in AD by studying well characterized early 
stage AD animal models.  
Materials and methods 
Animals 
The AβPPswe/PS1dE9 (AβPP/PS1) founder mice 
were originally obtained from John Hopkins 
University, Baltimore, MD, USA (D. Borchelt and J. 
Jankowsky, Dept. of Pathology) [37, 38] and a colony 
was first established at the University of Kuopio, 
Finland and thereafter a colony was bred at the 
Central Animal Facility at Radboud university 
medical center, The Netherlands. In short, mice were 
created by co-injection of chimeric mouse/human 
AβPPswe (mouse AβPP695 harbouring a human Aβ 
domain and mutations K595N and M596L linked to 
Swedish familial AD pedigrees) and human PS1-dE9 
(deletion of exon 9) vectors controlled by independent 
mouse prion protein promoter elements. The two 
transfected genes co-integrate and co-segregate as a 
single locus [38]. This line was originally maintained 
on a hybrid background by backcrossing to 
C3HeJ×C57BL/6J F1 mice (so-called pseudo F2 stage). 
For the present work, the breeder mice were 
backcrossed to C57BL/6J for fourteen generations to 
obtain mice for the current study. Before the actual 
experiments, animals were housed socially with a 
maximum of six animals per cage, with room 
temperature at 21°C, and artificial 12:12h light:dark 
cycle (lights on at 7 a.m.). Food and water were 
available ad libitum. The experiments were performed 
according to Dutch federal regulations for animal 
protection and were approved by the Veterinary 
Authority of Radboud university medical center, 
Nijmegen, The Netherlands, and the Animal 
Experiment Committee (called the 
Dierexperimentencommissie or DEC, RU-DEC 
2011-058) of the Radboud university, Nijmegen, The 
Netherlands. The reporting of the animal experiments 
conforms with the ARRIVE guidelines [39]. 
For the present experiment, we used a total of 17 
16-month-old months old male mice (ten WT 
littermates, and seven AβPP/PS1 mice); at eighteen 
months of age, all animals completed the experiments 
and were euthanized. All behavioural and MRI 
experiments were performed in the Preclinical 
Imaging Centre (PRIME) of the Radboud university 
medical center between 8 a.m. and 6 p.m.. 
Study design, randomization, blinding, and 
sample size 
This was a single-institution, randomized, and 
double-blind controlled study (blinded for 
investigators and outcomes assessor) conducted at the 
preclinical imaging center (PRIME) of the 
Radboudumc (Nijmegen, the Netherlands). Per 
experimental subgroup, the selection of animals was 
randomized. All animals completed the study, no 
animals were replaced. The sample size of minimal 6 
mice per experimental group was chosen based on 
formal calculation of power as described in the 
approved protocols (RU-DEC 2011-058; WP: 110149) 
and using results from our previous study [40]. At 16, 
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17, and 18 months of age systolic blood pressure 
measurements were performed. At 17 months of age 
(WT: 16,8±0,03; AβPP/PS1: 16,6±0,04) all animals 
underwent behavioural testing in the open field and 
Morris water maze (MWM) and subsequently MRI 
measurements at 18 months of age (WT: 18.0±0,02; 
AβPP/PS1: 17,9±0,05). 
No animals were excluded from analysis. Post 
mortem immunohistochemical and biochemical 
procedures were performed on all brains. 
Tail-cuff plethysmography 
Mice were trained for two consecutive days in 
the warmed tail-cuff device (IITC Life Scientific 
Instruments, Woodland Hills, CA) to accustom them 
to the procedure. Starting from sixteen months of age 
and being repeated at seventeen and eighteen month 
of age, SBP was measured for two consecutive days 
monthly in trained, conscious and preheated mice 
using computerized tail-cuff plethysmography (IITC 
Life Scientific Instruments, Woodland Hills, CA), as 
previously described [41-44]. 
Behavioral analyses 
The results of the behavioral analyses are placed 
in the supplementary material. 
Morris water maze 
The Morris water maze (MWM) is used to test 
spatial learning and memory in rodents. In short, at 17 
months of age mice were placed in a circular pool, 
filled with opaque water, and were trained to find a 
submerged platform in the northeast (NE) quadrant 
of the pool by using distant visual cues.  
Acquisition (spatial learning) 
Mice were trained to find the location of the 
submerged escape platform in 4 acquisition trials 
(maximal swimming time 120 s; 30 s on the platform; 
inter-trial interval 60 min) per day during 4 
consecutive days. The latency time (s) to find the 
hidden platform was scored. Starting positions were 
south (S), north (N), east (E) and west (W). After the 2 
min swim the mice were placed back in their home 
cage, and a paper towel was available inside the cage 
for additional drying. 
Probe (spatial memory) 
At the start of the fifth day, mice performed a 
single probe trial (starting position: S), in which the 
platform was removed from the swimming pool. Mice 
were allowed to swim for 120 s and the time spent 
swimming and searching in the NE quadrant (where 
the platform had been located) was recorded. 
Open field 
Locomotion and explorative behavior were 
evaluated for 30 minutes in the open field at 17 
months of age, as previously described [40, 45, 46]. 
Using EthoVision XT10.1 (Noldus, Wageningen, The 
Netherlands), locomotion was automatically 
recorded. The floor of the arena was divided into 
center, periphery, and corners. The frequency of 
entering these zones was measured automatically. In 
addition, exploration was manually scored (walking, 
sitting, wall leaning, jumping, rearing, grooming) and 
analyzed as described previously [47, 48]. 
MRI protocol  
Following the behavioral examinations, at 18 
months of age MRI measurements were performed on 
an 11.7 T BioSpec Avance III small animal MR system 
(Bruker BioSpin, Ettlingen, Germany) equipped with 
an actively shielded gradient set of 600 mT/m and 
operating on the Paravision 5.1 software platform 
(Bruker, Karlsruhe, Germany). We used a circular 
polarised volume resonator for radiofrequency 
transmission and an actively decoupled mouse brain 
quadrature surface coil with integrated combiner and 
preamplifier for receive (Bruker BioSpin). For the 
imaging procedure, the animals were anesthetized 
with isoflurane (3.5% for fast induction and 1.8% for 
maintenance) in a 2:1 oxygen and N2O mixture 
(normal gas condition) or in a 3:0 oxygen and N2O 
mixture (vasoconstriction), and placed in a 
stereotactic holder to prevent unwanted movement 
during the scanning. Body temperature was 
monitored with a rectal temperature probe and 
maintained at 37˚C with heated airflow. Respiration 
of the animal was monitored using a pneumatic 
cushion respiratory monitoring system (Small Animal 
Instruments Inc, NY, USA). First gradient echo 
T2*-weighted images covering the entire mouse brain 
were acquired in three directions for anatomical 
reference using previously described acquisition 
parameters [49]. 
Cerebral blood flow 
MR perfusion data were measured with 
flow-sensitive alternating inversion recovery (FAIR) 
MRI techniques; from a series of echo planar imaging 
(EPI)-images in three different regions of interest 
(ROI) were evaluated [50, 51] in the cerebral cortex (all 
cortical regions above corpus callosum), 
hippocampus, and thalamus according to the Franklin 
- Paxinos atlas [52]. Twelve images with increasing 
inversion times (TIs; 40–3000 ms) were obtained for 
the T1 calculations, accounting to a total scan time of 
12 min. Inversion recovery data from the imaging 
slice were acquired after selective inversion 
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interleaved with nonselective inversion. To evaluate 
vasoreactivity, a 2:1 oxygen and N2O mixture (normal 
gas condition) and a 3:0 oxygen and N2O mixture 
(vasoconstriction) were used. To calculate regional 
CBF we used the protocol that is described in [49].  
Diffusion tensor imaging 
Diffusion of water was imaged as described 
previously [40, 45, 53]. In short, 22 axial slices 
covering the whole brain were acquired with a 
four-shot SE-EPI protocol. B0 shift compensation, 
navigator echoes and an automatic correction 
algorithm to limit the occurrence of ghosts and 
artefacts were implemented. Encoding b-factors of 0 
s/mm2 (b0 images; 5×) and 1000 s/mm2 were used 
and diffusion-sensitizing gradients were applied 
along 30 non-collinear directions in three-dimensional 
space.  
The diffusion tensor was estimated for every 
voxel using the PATCH algorithm [54]; mean water 
diffusivity (MD) and fractional anisotropy (FA) were 
derived from the tensor estimation following a 
protocol as described elsewhere [45]. MD and FA 
values were measured in several white matter (WM) 
and grey matter (GM) areas, manually selected based 
on an anatomical atlas [52]. 
Resting state fMRI 
Subsequently after the acquisition of the 
anatomical reference images, resting state fMRI 
(rsfMRI) datasets were acquired using a single-shot 
spin-echo sequence with echo-planar readout (SE-EPI) 
sequence. Six hundred repetitions with a repetition 
time (TR) of 1.8 s and echo time of 16.9 ms were 
recorded for a total acquisition time of 18 min. The 
rsfMRI datasets were first realigned using a 
least-squares method and rigid-body transformation 
with Statistical Parametric Mapping (SPM) mouse 
toolbox (SPM5, University College London; 
http://www.fil.ion.ucl.ac.uk/spm/; Sawiak et al., 
2009). Mean and maximum displacement across the 
six degrees of freedom (along the x-, y-, and z-axes 
and on three rotation parameters pitch, roll, and yaw) 
were measured in each mouse. The mean SE-EPI 
images for each mouse were then used to generate a 
study-specific template through linear affine and 
nonlinear diffeomorphic transformation (ANTs. v1.9; 
http://picsl.upenn.edu/ANTS/). Visual inspection of 
the normalised dataset was performed to screen for 
possible normalization biases. On the template, 12 
areas were selected in left and right hemisphere. The 
selected regions were based on previous work 
concerning functional connectivity in mice [55], and 
included: left and right dorsal hippocampus, left and 
right ventral hippocampus, left and right auditory 
cortex, left and right motor cortex, left and right 
somatosensory cortex, and left and right visual cortex. 
All cortical ROIs were selected 1–2 voxels away from 
the edge of the cortex, to minimise the impact of 
susceptibility artefacts, which are more prominent in 
areas close to tissue interfaces (e.g., near the skull or 
near the ear canals). In-plane spatial smoothing (0.4 × 
0.4 mm), linear detrending, and temporal high-pass 
filtering (cut-off at 0.01 Hz) were applied to 
compensate for small across-mouse misregistration 
and temporal low-frequency noise. FC group 
comparison between ROIs were calculated from the 
BOLD time series using total and partial correlation 
analyses implemented in FSLNets (FSLNets v0.3; 
www.fmrib.ox.ac.uk/fsl). Pearson's correlation values 
were Fisher transformed to Z-scores for group 
comparisons and statistical analysis. 
Post mortem brain tissue preparation 
Directly following the MR measurements at 18 
months of age, anaesthetized mice were sacrificed by 
transcardial perfusion with 0.1M phosphate buffered 
saline (PBS) at room temperature. The perfused brains 
were cut mid-sagittally and the right hemispheres 
were snap frozen in liquid nitrogen and stored at 
-80°C, before further biochemical processing. The left 
hemispheres were immersion fixated for 15h at 4°C in 
4% paraformaldehyde fixative and thereafter stored in 
0.1M PBS with 0.01% sodium azide at 4°C for 
immunohistochemical staining. 
Immunohistochemistry 
Eight series of 30 µm coronal sections were cut 
through the brain using a sliding microtome (Microm 
HM 440 E, Walldorf, Germany) equipped with an 
object table for freeze sectioning at -60°C.  
For every staining, one complete series with 240 
µm distance between the sections was used. 
Immunohistochemistry was performed using 
standard free-floating labeling procedures, as 
described previously, and was carried out on a shaker 
table at room temperature. [40].  
Postsynaptic density (PSD) was visualized with 
anti-PSD-95 antibody (1:2000; Abcam, catalog 
#ab18258, RRID:AB_444362) using one subseries of 
brain sections per animal. Donkey anti-rabbit biotin 
1:1500 (Jackson ImmunoResearch, West Grove, PA, 
USA) was used as secondary antibody. 
To visualize immature neurons we used an 
anti-doublecortin (DCX) antibody (1:4000; polyclonal 
goat anti-doublecortin (C18): sc-8066, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) with one 
subseries of brain sections per animal. Being a 
microtubule-associated protein, Doublecortin is 
exclusively found in somata and processes of 
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migrating and differentiating neurons [56, 57]. 
Donkey-goat biotin 1:1500 (Jackson ImmunoResearch, 
West Grove, PA, USA) was used as secondary 
antibody. 
To visualize and quantify the amount of 
macrophages and microglia, an anti-ionized calcium 
binding adapter molecule 1 (IBA-1) antibody (1:1500; 
polyclonal goat anti-IBA1 (C18); Abcam Inc., 
Cambridge, UK) was used with one subseries of brain 
sections per animal. Donkey-goat biotin 1:1500 
(Jackson ImmunoResearch, West Grove, PA, USA) 
was used as secondary antibody. 
The amount of glucose transporter type 1 
(GLUT-1) was visualized using an anti-GLUT-1 
antibody (1:10.000; rabbit anti GLUT-1 transporter, 
Chemicon AB 1340, Chemicon International, Inc., 
Temecula, CA, USA). Donkey-rabbit biotin 1:1500 
(Jackson ImmunoResearch, West Grove, PA, USA) 
was used as secondary antibody.  
Results of all immunohistochemical stainings for 
PSD-95, DCX, IBA-1, and GLUT-1 can be found in the 
supplementary material. 
Quantification – PSD-95 
The stained sections were analyzed using a Zeiss 
Axioskop microscope equipped with hardware and 
software of Microbrightfield (Williston, VT, USA). 
Brain regions were based on the mouse brain atlas of 
Franklin & Paxinos [52] and quantified in five regions 
of the hippocampus: the inner molecular layer (IML), 
outer molecular layer (OML), cornu ammonis 1 
(CA1), CA2 and CA3. Additionally, two regions in the 
cortex corresponding to the visual and somatosensory 
cortex were analyzed. The relevant regions were 
digitized at 100 times magnification with immersion 
oil using Stereo Investigator. The quantification of the 
photographs was performed using Image J (Image J, 
U. S. National Institutes of Health, and Bethesda, 
Maryland, USA). The contrast was manually 
enhanced, following the same procedure for all 
digitized images, and the amount of tissue stained 
was measured with a threshold-based approach.  
Quantification – DCX, IBA-1 & GLUT-1 
Brain sections between bregma -1.46 and -2.30 
[52] were preselected for quantification. 
Quantification was done at a 5x magnification using 
an Axio Imager (A2, Zeiss Germany). ImageJ 
(National Institute of Health, Bethesda, MD, USA) 
was used to analyze the regions of interest: Cortex 
(IBA-1 & GLUT-1), hippocampus (DCX, IBA-1 & 
GLUT-1).  
Biochemical analyses 
Serum and brain sterol levels were measured by 
gas-chromatography-mass-spectrometry-selected-ion
-monitoring (GC-MS-SIM) as described in detail 
previously [58]. The cerebellum of the right 
hemisphere was homogenized and sterols were 
extracted overnight by chloroform/methanol 
trimethylsilylation prior to GC-MS-SIM analysis [58]. 
Brain fatty acid analyses were performed with a part 
of the brain homogenate (olfactory bulb and part of 
frontal cortex), as described previously [45].  
Statistics 
For the statistical analysis, IBM SPSS 22 software 
(IBM Corporation, New York, NY, USA) was used.  
Multivariate ANOVA (Repeated measures 
ANOVA for the MWM and SBP data) with Bonferroni 
corrections was conducted with 
between-group-factors genotype to analyze possible 
differences in all the other parameters. Statistical 
significance was set at p ≤ 0.05, while a tendency was 
set at 0.05 < p < 0.08. All data are expressed as mean ± 
SEM. 
Results 
Body Weight 
18-month-old AβPP/PS1 mice had the same 
body weight as their WT littermates before both MR 
scan sessions (Fig. 1A, F(1,15)=2.7, p<0.124).  
Systolic blood pressure 
Using tail-cuff plethysmography to measure 
systolic blood pressure (SBP), AβPP/PS1 mice 
demonstrated an increased SBP compared to their WT 
littermates from 16 to 18 months of age (Fig. 1B, 
F(1,15)=5.6, p<0.032). Both AβPP/PS1 and WT mice 
exhibited a decrease in SBP over time from 16 to 18 
months of age (Fig. 1B, F(2,30)=8.1, p<0.002). 
 
 
 
Figure 1. Body weight (A) and systolic blood pressure (B, SBP) of 
AβPP/PS1 and wild-type (WT) mice. (A) 18 month old AβPP/PS1 mice 
showed no difference in body weight compared to their WT littermates 
(p<0.124). (B) SBP was measured each experimental month for two consecutive 
days in trained, conscious and preheated mice using computerized tail-cuff 
plethysmography. Here, AβPP/PS1 mice had a higher SBP than their WT 
littermates from 16 to 18 months of age (p<0.032). SBP of both AβPP/PS1 and 
WT mice decreased over time from 16 to 18 months of age (p<0.002). 
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MR measurements 
Cerebral blood flow and vasoreactivity 
To study the effect of genotype differences on 
cerebrovascular health, CBF (Fig. 2A) and 
vasoreactivity (Fig. 2B) were measured with FAIR 
ASL using normal (200 O2 : 100 N2O mL/min) and 
vasoconstrictive (300 O2 : 0 N2O mL/min) gas 
conditions in three regions of interest (ROI): cortex, 
hippocampus and thalamus. Under normal gas 
condition a decreased CBF was observed in the cortex 
(F(1,14)=4.2, p<0.060) and thalamus (F(1,14)=10.5, 
p<0.007) of AβPP/PS1 mice compared to their WT 
littermates. In addition, under vasoconstrictive 
condition our AD model mice had again a lower 
thalamic CBF (F(1,14)=5.1, p<0.040) than the WT mice. 
Both AβPP/PS1 and WT mice showed an intact 
vasoreactivity in the cortex (AβPP/PS1, F(1,6)=6.2, 
p<0.048; WT, F(1,8)=13.7, p<0.006) and thalamus 
(AβPP/PS1, F(1,6)=13.2, p<0.011; WT, F(1,8)=35.4, 
p<0.001). In contrast, in the hippocampus only WT 
mice (F(1,8)=13.8, p<0.006) revealed an intact 
vasoreactivity, while AβPP/PS1 mice (F(1,6)=1.6, 
p<0.253) had an impaired vasoreactivity indicating an 
incapability to adapt to the vasoconstrictive gas 
condition. 
Diffusion tensor imaging 
Quantitative assessment of the diffusion tensor 
indices fractional anisotropy (FA); and mean 
diffusivity (MD) was performed for ROIs drawn in 
several white and gray matter regions to assess effects 
of AD-like pathology in 18-month-old AβPP/PS1 and 
WT mice (Fig. 2C+D). AβPP/PS1 mice showed 
impaired white matter integrity as indicated by a 
decrease in FA in the visual cortex, not being present 
in their WT littermates (Fig. 2C, F(1,9)=24.5, p<0.001). 
No genotype effect was present for the MD (Fig. 2D). 
 
 
Figure 2. Genotype effects on the cortical, hippocampal and thalamic cerebral blood flow (A, CBF) and vasoreactivity (B) using normal (200 O2 
: 100 N2O mL/min) and vasoconstrictive (300 O2 : 0 N2O mL/min) gas conditions in 18-month-old AβPP/PS1 and wild-type (WT) mice. 
Quantitative assessment of diffusion tensor derived indices was performed for several ROI (AUC= Auditory cortex, CC=Corpus callosum, 
F=Fornix, HC=Hippocampus, MC=Motor cortex, OT=Optic tract, SSC=Somatosensory cortex, VC=Visual cortex) drawn in white and gray 
matter to assess effects of AD-like pathology in 18-Month-old AβPP/PS1 and WT mice on fractional anisotropy (C) and mean diffusivity (D). (A) 
CBF was measured with flow-sensitive alternating inversion recovery MRI technique; from a series of echo planar imaging images. Under normal gas condition, 
AβPP/PS1 mice had a lower cortical (p<0.060) and thalamic (p<0.007) CBF than their WT littermates. Under vasoconstrictive gas conditions, AβPP/PS1 mice showed 
again a lower thalamic CBF (p<0.040) than their WT littermates. (B) Both AβPP/PS1 and WT mice showed an intact vasoreactivity in the cortex (AβPP/PS1, p<0.048; 
WT, p<0.006) and thalamus (AβPP/PS1, p<0.011; WT, p<0.001). In contrast, in the hippocampus only WT mice (p<0.006) revealed an intact vasoreactivity, while 
AβPP/PS1 mice (p<0.253) had an impaired vasoreactivity indicating an incapability to adapt to the vasoconstrictive gas condition. (C) AβPP/PS1 mice had a lower FA 
in the VC than WT mice indicating an impaired white matter integrity (p<0.001). (D) No genotype effect was found for the MD in all measured ROI. 
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Resting state fMRI 
To analyze the impact of AD-like pathology on 
the functional connectivity (FC) patterns at 18 months 
of age, rsfMRI data were statistically analyzed based 
on total correlation (Fig. 3A) and partial correlation 
(Fig. 3B). 
Total correlation analyses 
AβPP/PS1 mice showed no differences in FC, as 
analyzed with total correlations compared to their WT 
littermates (Fig. 3A). 
Partial correlation analyses 
In comparison with the total correlation analysis, 
partial correlation analysis accentuates the direct 
connectivity between two ROI, while regressing the 
temporal BOLD signal from all other ROI. Resulting 
connectivity was thresholded at |Z| > 1.0. For the 
partial correlations we found significant genotype 
effects at 18 months of age (Fig. 3B). AβPP/PS1 mice 
showed a disturbed FC between several brain regions. 
While revealing an increased FC between the left 
motor cortex to left auditory cortex (F(1,12)=5.5, 
p<0.037), AβPP/PS1 mice compared to their WT 
littermates demonstrated a decreased FC between left 
auditory cortex to left ventral hippocampus 
(F(1,12)=5.7, p<0.034) and left somatosensory cortex to 
left visual cortex (F(1,12)=6.3, p<0.028). 
Fatty acids in brain tissue  
Fatty acid content was determined in frontal 
cortex (Supplementary table 1). 
No genotype effects were found for the brain 
fatty acids palmitic acid, stearic acid, saturated fatty 
acid, oleic acid, and mono-unsaturated fatty acid. 
However, AβPP/PS1 mice showed increased 
arachidonic acid (F(1,15)=6.8, p<0.020), increased total 
omega-6 (F(1,15)=4.1, p<0.061), a decreased DHA 
(F(1,15)=9.6, p<0.008), a decreased overall omega-3 
(F(1,15)=10.6, p<0.006), and a resulting decreased 
omega-3/omega-6 ratio (F(1,15)=8.6, p<0.011).  
Sterol levels  
Sterol levels were determined in the blood serum 
(Supplementary table 2) and in the cerebellum of the 
brain (Supplementary table 3).  
Blood serum 
No genotype effects were found in levels of 
cholestanol, lathosterol, campesterol, campestanol, 
stigmasterol, sitosterol, sitostanol, avenasterol, 
brassicasterol, lanosterol, desmosterol, 
dihydro-lanosterol, 24OH-cholesterol, 
7αOH-cholesterol, 27OH-cholesterol, and global 
cholesterol. 
Cerebellum 
In brain tissue of 18-month-old AβPP/PS1 mice, 
levels of dihydro-lanosterol (F(1,15)=5.8, p<0.030) 
were higher than in the brain tissue of their WT 
littermates. No genotype effects were revealed for the 
sterol levels of cholestanol, lathosterol, campesterol, 
stigmasterin, sitosterol, lanosterol, desmosterol, 
24OH-cholesterol, 27OH-cholesterol, and global 
cholesterol. 
 
 
Figure 3. Resting-state functional connectivity (FC) based on total (A) and partial (B) correlation analyses of 12 ROI in the brain of in 
18-Month-old AβPP/PS1 and WT mice. (A) For the overall correlations no significant genotype effects were detected in the dorsal (DHC) and ventral 
hippocampus (VHC), and auditory (AUC), motor (MC), somatosensory (SSC), and visual cortices (VC). (B) AβPP/PS1 mice showed a disturbed FC between several 
brain regions. Between the left motor cortex to left auditory cortex (p<0.037) AβPP/PS1 mice had a higher FC than their WT littermates, while showing a decreased 
FC between left auditory cortex to left ventral hippocampus (p<0.034) and left somatosensory cortex to left visual cortex (p<0.028).
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Discussion 
Hypertension is the most common 
cardiovascular risk factor [36, 59-65], and associated 
with all (other) key markers of AD such as presence of 
amyloid-β (Aβ) plaques, neurofibrillary tangles, and 
brain atrophy [64]. The increasing prevalence of 
hypertension due to the aging world population and 
growing prevalence of obesity could also increase the 
number of AD patients, since midlife hypertension 
almost doubles the risk of developing AD in later life 
[36, 66]. In agreement with this, the AβPP/PS1 
AD-like model mice used in the present study, 
demonstrated an increased systolic blood pressure 
(SBP) and concomitant decreased regional CBF in the 
cortical and thalamic areas, decreased vasoreactivity 
of the circulation of the hippocampus, and impaired 
cognition. The WT and AβPP/PS1 mice showed a 
decrease in SBP over time, while the AβPP/PS1 mice 
always demonstrated a higher SBP than their WT 
littermates. This is in line with the AGES-Reykjavik 
study which has shown that midlife hypertension 
combined with a lower late-life BP is associated with a 
lowered total brain and gray matter volume [67]. 
Long-standing hypertension stimulates 
atherosclerosis and vascular remodeling leading to 
increases in wall thickness. Arterial stiffness and 
severe atherosclerosis can lead to an increase in pulse 
pressure [68]. An increased pulse pressure is 
correlated with a higher risk of AD in older adults 
[68]. In the Rotterdam study the presence of 
atherosclerotic plaques or wall thickening has been 
associated with dementia and its two major subtypes 
AD and vascular dementia [66]. In accordance to 
previous research, this AD-like mouse model suffers 
from early-impaired cerebrovascular autoregulation 
and CBF, but also shows abnormalities in the cortical 
microvasculature [69-72]. These results support the 
significant reduction in regional and global CBF as 
identified in studies on MCI and AD patients [73]. A 
lowered CBF is a common feature in the early phase 
of AD, which may possibly be caused by an 
accumulation of Aβ in the vessel walls or in close 
vicinity of the blood vessels [27, 74, 75]. Furthermore, 
the impaired vasoreactivity in our transgenic mice is 
also a clinical hallmark of AD [76]. Aβ has shown to 
directly enhance the vasoconstriction of the cerebral 
arteries and to stimulate selected constrictor 
responses, resulting in a reduced CBF [74]. In 
addition, deposition of Aβ in the cerebral 
microvessels promotes vascular pathology and 
dysfunction [77-79], as embodied by the impaired 
hippocampal vasoreactivity in the brains of the 
AβPP/PS1 mice. Hypertension may contribute to this 
remodeling through increase in smooth muscle tone 
and damage of endothelial cell function resulting in 
arterial wall thickening and microvascular rarefaction 
[80]. In line with our research, Toth et al. 
demonstrated that in aging mice hypertension could 
induce an impaired cerebrovascular autoregulation 
[81], cerebromicrovascular injury and 
neuroinflammation. In the present study we 
investigated brain diffusivity with DTI as an imaging 
biomarker for white and gray matter integrity. FA is a 
marker of the degree of myelination and fiber density 
of white matter, while MD characterizes an inverse 
measure of the membrane density and is sensitive to 
cellularity, edema, and necrosis in grey matter (GM) 
[82-84]. In addition to an impaired cerebrovascular 
function, a reduced FA value of the visual cortex was 
found in our AD model mice indicating a subtle 
change in microstructural integrity. This impaired 
microstructural integrity could imply axonal 
degeneration or demyelination [84] in the visual 
cortex. Nevertheless, no genotype effects were found 
for MD, being considered to be more informative for 
grey matter regions like the visual cortex. In our 
previous research using DTI in 12-month-old WT and 
AβPP/PS1 mice as well, fiber tract volume reduction, 
loss of axonal neurofilaments, and myelin breakdown 
in axonal bundles of several white matter regions (i.e. 
body of the corpus callosum) were detected in 
AβPP/PS1 mice compared to WT [85]. In this recent 
study minor genotype effect on FA and no genotype 
effects on MD were found. One reason for these 
missing genotype effects could be that already in 
normal aging significant white matter deterioration 
occurs due to myelin degeneration [86]. Therefore, 
myelin degeneration in our 18 months WT mice may 
mask partly the significant changes regarding 
structural connectivity in APP/PS1 mice. 
Nevertheless, in line with the loss of structural 
connectivity, a disturbed FC pattern in cortical and 
hippocampal brain regions was revealed in the 
18-month-old AβPP/PS1 mice. In support, a mouse 
model for cerebral amyloidosis demonstrated a 
compromised FC affecting the sensory motor cortex 
already in pre-plaque stage [87]. Our latter results are 
in accordance with clinical studies, in which a 
decreased FC was also demonstrated in AD patients 
[29-31].  
A limiting factor of the acquired FC results is 
that the rsfMRI measurements are acquired in 
isoflurane anesthetized mice. Fortunately, using 
rsfMRI a general structure of the functional networks 
transcending levels of consciousness was detected in 
both preclinical and clinical studies [88-90]. Notably, 
under isoflurane anaesthesia a bilateral cortical 
connectivity in several cortical regions was measured 
[91, 92]. Nevertheless, also contradictory results were 
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detected in isoflurane anesthetized mice showing not 
the same level of bilateral connectivity [55, 93]. 
However, in our previous and recent studies using 
isoflurane as anaesthesia, we confirmed the presence 
of networks in several well defined cortical and 
subcortical brain regions in two different murine 
models for vascular risk factors for AD [94, 95]. In our 
previous work we confirmed that both FC and CBF 
are dependent on isoflurane concentrations, and both 
FC and CBF decline with concentrations of isoflurane 
>2.2%, but do not further decline below a 
concentration of 2.2% [95]. Therefore, using the low- 
dose isoflurane (~1.7%) in this recent experiment will 
preserve the resting-state networks and will not 
interfere with the outcome of this study, as all animals 
were kept under the same low isoflurane 
concentration. 
The combination of impaired cerebral 
hemodynamics, disturbed structural and functional 
connectivity, may underlie the impaired spatial 
learning capability found in the MWM. Here, the 
AβPP/PS1 mice needed more time to learn the 
position of the hidden platform. Moreover, these 
transgenic mice demonstrated a larger swim distance 
and higher swim velocity indicating an increased 
usage of non-spatial search strategies instead of 
hippocampus-dependent search strategies to find the 
hidden platform in the MWM [96, 97]. The behavior of 
the APP/PS1 mouse has been well-characterized. 
Mirroring the cognitive impairment being present in 
early AD patients, this cognitive deficit is a 
well-known feature of this AD mouse model. While at 
4 and 7 months of age no learning deficit could be 
determined in AβPP/PS1 mice [98, 99], these AD 
model mice tend to exhibit an impaired memory 
capacity at 8 months of age in our earlier studies [48] 
and a significantly impaired spatial memory at 12 
months of age, as demonstrated in studies from 
Lalonde et al. [100]. In fear-conditioning tests Kilgore 
et al. showed at already six months of age an impaired 
contextual memory in the APP/PS1 mouse model 
[101]. However, Webster et al. performed recently a 
comprehensive behavioral analysis of a knock-in 
AβPP/PS1 mouse model [102] using four different 
age groups (7, 11, 15, and 24 months) in which 
cognitive deficits in spatial reference memory (radial 
arm water maze) appeared from 11 months of age and 
becoming apparent as the disease progressed and 
recognition memory (novel object recognition) was 
demonstrated just from 15 months of age [102]. In line 
with previous results from our lab on younger 
(8-/12-/15-month-old) AβPP/PS1 mice [40, 48], also 
our 18-month-old AβPP/PS1 mice exhibited an 
increased locomotor activity and anxiety-related 
behavior in the open field. Being linked to elevated 
anxiety levels, this heightened activity has been 
observed in many transgenic AD model mice 
[103-105]. This hyperactivity and anxiety-related 
behavior resembles restlessness and anxiety-related 
symptoms found in up to 71% of AD patients [106, 
107]. The increased anxiety of our mice could reveal a 
possible pathological mechanism for the elevation in 
SBP. This phenotype of anxiety is an expression of a 
stressful chronic condition. Therefore, it is well 
known that mental stress is able per se to provoke an 
increase in blood pressure in mice [108, 109]. The 
influence of the overexpression of AβPP and PS1 on 
cognition is well-characterized in several AD mouse 
models, while the non-cognitive behavior has not 
been considered as systematically [110]. Pugh et al. 
demonstrated reduced spontaneous motor activity, 
disinhibition, heightened frequency and duration of 
feeding bouts, decreased body weight and, by 10 
months, increased activity over a 24h period in both 
female and male AβPP/PS1 mice [110]. In addition, 
male mice also expressed a heightened aggression 
relative to WT controls [110]. In the postmortem part 
of the study we revealed a decreased postsynaptic 
density and less DCX+ cells in the hippocampus of 
AβPP/PS1 mice indicating respectively a lowered 
synaptogenesis and neurogenesis, which may be the 
cause of the profound cognitive impairment found in 
the MWM in this AD-like transgenic mouse model. 
Notably, in our earlier studies, AβPP/PS1 mice 
showed decreased neurogenesis combined with a 
lowered hippocampal CBF already at 12-month of age 
[40, 49]. Moreover, in these younger 12-month-old 
AβPP/PS1 mice Zerbi et al. also detected impaired 
structural connectivity in the corpus callosum, 
fimbria, and cortex measured also via DTI [49]. This 
decrease in hippocampal CBF was no longer observed 
in the 18-month-old AβPP/PS1 mice granting a 
possible pathological timeframe starting with an 
impaired hippocampal CBF provoking a decreased 
synapto- and neurogenesis resulting in an impaired 
cognition. In another study, Ermini et al. showed as 
well a decreased neurogenesis in younger (8 months 
of age) AβPP/PS1 and (5 months of age) AβPP23 mice 
[111]. In many transgenic mouse models of AD an 
increased neuroinflammation has been observed 
reporting modulation of cytokine levels, activation of 
microglia and in some cases an activation of the 
complement system [112]. In the early pre-plaque 
stages of transgenic AD mice and, to a much lesser 
extent, in old WT mice highly activated microglia 
have been found [113-117]. In addition, Aβ-plaques in 
AD are engulfed by activated microglia [117]. To 
measure neuroinflammation, we 
immunohistochemically stained the mouse brains 
with ionized calcium-binding adapter molecule 1 
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(IBA-1) being a marker for activated microglia 
[118-120]. Here, in our AD model mice more IBA+ 
cells were detected in cortical regions compared to 
their WT littermates. In accordance to the results of 
Minogue et al., in this mouse model after 14 months of 
age an age-associated dysregulation of microglial 
activation is coupled with an enhanced blood-brain 
barrier permeability [114]. Furthermore, Meadowcroft 
et al. demonstrated activated microglial cells 
surrounding Aβ plaques in the brain of AβPP/PS1 
mice. In accordance to our previous study, 
18-month-old AβPP/PS1 mice did not show any 
differences in hippocampal capillary density 
measured via immunohistochemical staining for 
GLUT-1 [121]. Notably, these mice exhibited the 
highest level of Aβ in combination with hippocampal 
atrophy [121]. While 8-month-old AβPP/PS1 mice 
demonstrated also an increased amount of Aβ 
deposition in the dentate gyrus, but did not show any 
differences in hippocampal atrophy [121]. Besides all 
other AD-like pathological changes in this AD mouse 
model, we also detected an increase in cerebral 
omega-6 fatty (n6) acid content (especially 
arachidonic acid, ARA) combined with a decrease in 
cerebral omega-3 (n3) fatty acid content (in particular 
docosahexaenoic acid, DHA) resulting in a 
pronounced decreased n3/n6-ratio, which is thought 
to elevate the risk for AD [122, 123]. In accordance to 
our results, Dutch drug-naïve patients with mild AD 
(Mini-Mental State Examination (MMSE) = 25.0) 
showed a decreased relative content of n3 fatty acids 
(including DHA) and an increased relative content of 
ARA in erythrocyte membranes compared to a group 
of Dutch healthy controls (MMSE = 29.0) [124]. In 
accordance, ARA is a mediator of inflammatory 
pathways, and its metabolites are involved in the 
production of Aβ and in the pathogenesis of AD [125]. 
In our previous research using the same transgenic 
mouse model, a multi-nutrient diet was able to induce 
a pronounced shift in n3/n6 ratio in favor of the n3 
fatty acids as compared to the control diet [40]. Here, 
the reduction of the relative n6 content was mainly 
caused by a decrease in ARA, while the higher n3 
content was mainly caused by an increase in DHA. 
Fabelo et al. revealed that AβPP/PS1 mice show a 
more rapid lipid raft aging compared to WT, which is 
related to an increased saturation of phospholipids 
(higher saturated fatty acids content and decreased 
content of the long chain unsaturated fatty acids ARA 
and DHA) and increased sphingomyelin levels rather 
than to alterations in cholesterol [126]. Moreover, 
Fabelo et al. demonstrated that both levels of ARA and 
DHA were gradually lowered with age in AβPP/PS1 
mice, with its maximal reduction of approximately 
50% at 14 months of age [126]. In our recent study the 
aged 18-month-old AβPP/PS1 mice demonstrated a 
pronounced decreased n3/n6-ratio in the frontal 
cortices due to a decrease in DHA and increased ARA. 
This contradictory data on ARA levels may be 
explained by age and the brain area measured, as 
Fabelo et al. analyzed homogenized cortex of a total 
hemisphere. Notably, Perez et al. revealed that both 
male and female 6-month-old AβPP/PS1 mice show 
neither a change in ARA nor a decrease in DHA brain 
fatty acid content [127] indicating the pathological 
role of aging in disturbing cerebral membrane 
composition. Notably, a novel finding is the increased 
level of dihydro-lanosterol in our AD-model mice, 
being an intermediate in the cholesterol synthesis. 
Nevertheless, no genotype effects on cholesterol levels 
in blood and brain tissue were found. Decreased brain 
cholesterol levels were measured in our previous 
research using 15-month-old AβPP/PS1 mice 
compared to their WT littermates [48]. In addition, 
mice fed a high cholesterol-containing typical western 
diet showed a significant decreased regional cerebral 
blood volume compared to mice fed a standard 
control chow diet [48]. Notably, Park et al. showed an 
increased Aβ synthesis and senile Aβ plaque 
deposition only in female AD model (Tg2576) mice 
when using lovastatin (a blood-brain barrier crossing 
inhibitor of the cholesterol biosynthesis pathway) 
[128]. Dysregulation of the cerebral cholesterol 
homeostasis has been increasingly associated with 
chronic neurodegenerative disorders, including AD, 
Huntington’s disease, and Parkinson’s disease [129]. 
Furthermore, the E4 isoform of apolipoprotein E, 
being a cholesterol-carrying protein, is linked to an 
increased risk of developing AD [129].  
In conclusion, in this study we detected an 
increased SBP, impairments in cerebral 
hemodynamics resulting in an impaired cognition 
and structural and functional connectivity, increased 
locomotor activity, and anxiety-related behavior in an 
AD-like mouse model. In accordance, already in 4.5 
months old AβPP/PS1 mice Cifuentes et al. indicated 
that hypertension is able to accelerate the 
development of Alzheimer disease-related structural 
and functional alterations, partially through cerebral 
vasculature impairment and reduced nitric oxide 
production [130]. Future research should also 
consider gender differences in these AβPP/PS1 mice. 
In detail, male mice develop Aβ plaques more rapidly 
than female mice, being saturated at nine months of 
age, while in female mice plaque accumulation does 
not reach its maximum in female mice until around 12 
months of age [131]. Notably, using both male and 
female 4-, 12-, and 17-month-old AβPP/PS1 mice 
Wang et al. demonstrated that female AβPP/PS1 mice 
have a higher hippocampal Aβ40 and Aβ42 levels 
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than male AβPP/PS1 mice at 4 months of age Aβ and 
female AβPP/PS1 mice had a heavier Aβ burden and 
higher plaque number compared to male mice of the 
same age, both at 12 and at 17 months of age [132]. 
Our results indicate that vascular impairment plays 
an important role in the very early stage of AD but 
whether it is a causative factor or just a contributor 
aggravating the disease progress, remains to be 
elucidated. Thus, future therapeutic approaches 
should focus on (cerebro)vascular impairment as a 
promising strategy for the prevention of AD. The 
present AD mouse model showing hypertension and 
cerebral circulation impairment could serve as 
translational tool for the development of treatments to 
inhibit neurodegenerative diseases like AD already in 
the prodromal phase of the disease.  
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